GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.
You may also be interested in...
GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study
Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.
GSK’s Promacta Cleared For Use With Interferon In Hep C Patients
The new indication fills an unmet need in a population of patients who have a short window to cure chronic hepatitis C infection before liver damage becomes too great for treatment, but for whom interferon-based therapy – currently their only option - is not indicated because of low platelet levels.
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients